Figure 7C highlighted that, in addition to the aforementioned medications, ADM expression was also negatively correlated with RO-3306, WZ-1-84, WH-4-023, TGX221, and several tyrosine kinase inhibitors (TKIs), such as lapatinib, erlotinib, and dasatinib, which were crucial in anti-tumor therapy. Here, ADM is linked to neoplasm.